Abstract
The effect of pretreatment with ranitidine (150 mg twice daily for 5 days) on the disposition of lignocaine was examined in 10 healthy volunteers (five male, five female). Each subject received separate oral (250 mg) and intravenous (1.5 mg/kg) doses of lignocaine hydrochloride before and after ranitidine. Lignocaine systemic clearance was reduced by 9% (1.11 to 0.99 1 h-1 kg-1; P less than 0.01) following ranitidine pretreatment. The volume of distribution at steady-state was reduced by 15% (3.34 to 2.85 1 kg-1; P less than 0.005). Lignocaine oral clearance, elimination half-life and oral bioavailability were unchanged after ranitidine pretreatment. There was no sex difference in the effects of ranitidine pretreatment on lignocaine disposition. These results are consistent with small reductions in blood flow to the splanchnic and other vascular beds due to ranitidine.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Abernethy D. R., Greenblatt D. J., Eshelman F. N., Shader R. I. Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. Clin Pharmacol Ther. 1984 Feb;35(2):188–192. doi: 10.1038/clpt.1984.25. [DOI] [PubMed] [Google Scholar]
- Benet L. Z., Galeazzi R. L. Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci. 1979 Aug;68(8):1071–1074. doi: 10.1002/jps.2600680845. [DOI] [PubMed] [Google Scholar]
- Feely J., Guy E. Lack of effect of ranitidine on the disposition of lignocaine. Br J Clin Pharmacol. 1983 Mar;15(3):378–379. doi: 10.1111/j.1365-2125.1983.tb01514.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Feely J., Wilkinson G. R., McAllister C. B., Wood A. J. Increased toxicity and reduced clearance of lidocaine by cimetidine. Ann Intern Med. 1982 May;96(5):592–594. doi: 10.7326/0003-4819-96-5-592. [DOI] [PubMed] [Google Scholar]
- Feely J., Wilkinson G. R., Wood A. J. Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med. 1981 Mar 19;304(12):692–695. doi: 10.1056/NEJM198103193041202. [DOI] [PubMed] [Google Scholar]
- Hills M., Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol. 1979 Jul;8(1):7–20. doi: 10.1111/j.1365-2125.1979.tb05903.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mather L. E., Tucker G. T. Meperidine and other basic drugs: general method for their determination in plasma. J Pharm Sci. 1974 Feb;63(2):306–307. doi: 10.1002/jps.2600630232. [DOI] [PubMed] [Google Scholar]
- Somogyi A., Gugler R. Drug interactions with cimetidine. Clin Pharmacokinet. 1982 Jan-Feb;7(1):23–41. doi: 10.2165/00003088-198207010-00002. [DOI] [PubMed] [Google Scholar]
- Wing L. M., Miners J. O., Birkett D. J., Foenander T., Lillywhite K., Wanwimolruk S. Lidocaine disposition--sex differences and effects of cimetidine. Clin Pharmacol Ther. 1984 May;35(5):695–701. doi: 10.1038/clpt.1984.97. [DOI] [PubMed] [Google Scholar]